A randomised, phase II study of intetumumab, an anti-α(v)-integrin mAb, alone and with dacarbazine in stage IV melanoma

BACKGROUND: α(v) integrins are involved in angiogenesis and melanoma tumourigenesis. Intetumumab (CNTO 95) is a fully human anti-α(v)-integrin monoclonal antibody. METHODS: In a multicentre, randomised, phase II study, stage IV melanoma patients were randomised 1 : 1 : 1 : 1 to 1000 mg m(−2) dacarba...

Descripción completa

Detalles Bibliográficos
Autores principales: O'Day, S, Pavlick, A, Loquai, C, Lawson, D, Gutzmer, R, Richards, J, Schadendorf, D, Thompson, J A, Gonzalez, R, Trefzer, U, Mohr, P, Ottensmeier, C, Chao, D, Zhong, B, de Boer, C J, Uhlar, C, Marshall, D, Gore, M E, Lang, Z, Hait, W, Ho, P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172894/
https://www.ncbi.nlm.nih.gov/pubmed/21750555
http://dx.doi.org/10.1038/bjc.2011.183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172894/
https://www.ncbi.nlm.nih.gov/pubmed/21750555
http://dx.doi.org/10.1038/bjc.2011.183

Ejemplares similares